Drug profile · INN
opicapone
ONGENTYS
opicapone (ONGENTYS) is a catechol o-methyltransferase inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — opicapone
- US status
- approved
- Class
- Nervous system (N04)
- Route
- ORAL
- Patents
- 7
- Programs
- 1
- Data quality
- 0.89
Quick answer
opicapone (ONGENTYS) is a catechol o-methyltransferase inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Catechol O-methyltransferase inhibitor
Primary target: Catechol O-methyltransferase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
AU 2023244944
PRODRUGS OF OPICAPONE
granted -
WO 2022158991
TRAITEMENT DE LA DOULEUR ASSOCIÉE À LA MALADIE DE PARKINSON AVEC DE L'OPICAPONE EN COMBINAISON AVEC LA LÉVODOPA
granted -
WO 2022081033
OPICAPONE ET LÉVODOPA POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON
granted -
WO 2022025781
DISPERSION SOLIDE D'OPICAPONE
granted -
CA 3183290
COMPRIME COMPRENANT DE L'OPICAPONE
granted -
WO 2021182981
OPICAPONE MICRONISÉE
granted -
CA 3174918
OPICAPONE MICRONISEE
granted
Frequently asked questions
What is opicapone?
opicapone (ONGENTYS) is a catechol o-methyltransferase inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for opicapone?
ONGENTYS is a marketed brand name for opicapone. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of opicapone?
opicapone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.